<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02728167</url>
  </required_header>
  <id_info>
    <org_study_id>HIFU-AR</org_study_id>
    <nct_id>NCT02728167</nct_id>
  </id_info>
  <brief_title>Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy</brief_title>
  <acronym>HIFU-AR</acronym>
  <official_title>Randomized, Open-label, Phase II Study to Evaluate the Efficacy of High-Intensity Focused Ultrasound Assisted Hepatic Resection (HIFU-AR) on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether HIFU-assisted liver resection (HIFU-AR)
      results in reduced blood loss compared to standard liver resection in patients with LM.This
      is a prospective, monocentric, randomized (1:1 ratio), comparative, open-label Phase II
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalized blood loss (ml/cm2)</measure>
    <time_frame>During hepatectomy</time_frame>
    <description>To compare the blood loss during hepactectomy in patients treated by HIFU-AR versus standard liver resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total blood los (ml)</measure>
    <time_frame>During hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transection time</measure>
    <time_frame>During hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transection time/cm2 of liver area (min/cm2)</measure>
    <time_frame>During hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostasis time</measure>
    <time_frame>During hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clip density on the liver section area</measure>
    <time_frame>During hepatectomy</time_frame>
    <description>Number of clips/cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Pringle manoeuvre</measure>
    <time_frame>During hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients needing a blood transfusion</measure>
    <time_frame>During hepatectomy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with postoperative complications assessed using Dindo-Clavien classification</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Liver Metastasis</condition>
  <arm_group>
    <arm_group_label>Pre-coagulation by HIFU-AR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-coagulation of the liver parenchyma with HIFU and standard liver resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard liver resection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard liver resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pre-coagulation of the liver parenchyma with HIFU</intervention_name>
    <description>6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments</description>
    <arm_group_label>Pre-coagulation by HIFU-AR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years at the day of consenting to the study.

          -  Patients with liver metastases requiring a hepatectomy for ≥ 2 segments.

          -  ECOG PS ≤ 1.

          -  Adequate bone marrow and liver function at baseline as defined below:

               -  Platelet count ≥ 100 x 109/l, and hemoglobin of ≥ 9 g/dl),

               -  Total bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN.

          -  Recovered from prior anti-neoplasic treatment-related toxicity (grade &lt;2 persistent
             treatment-related toxicity as per CTCAE v4 are accepted).

          -  Willingness for follow-up visits.

          -  Covered by a medical insurance.

          -  Signed and dated informed consent document indicating that the patient has been
             informed of all aspects of the trial prior to enrolment.

        Exclusion Criteria:

          -  Patients having previously undergone

               -  a major hepatic surgery (i.e. more than 3 liver segments) or

               -  biliary major surgery.

          -  Patient with cirrhosis or sinusoidal obstruction syndrome with portal hypertension.

          -  Pregnant women (women of childbearing potential are required to have a negative
             pregnancy test within 72 hours prior to inclusion). A positive urine test must be
             confirmed by a serum pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel RIVOIRE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Bérard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen BLANC</last_name>
    <phone>04 78 78 29 67</phone>
    <email>ellen.blanc@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel RIVOIRE</last_name>
      <phone>+33 478 78 28 28</phone>
      <email>michel.rivoire@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Michel RIVOIRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatectomy</keyword>
  <keyword>Liver metastasis</keyword>
  <keyword>High-Intensity Focused Ultrasound</keyword>
  <keyword>Liver metastases (LM) requiring surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

